Open AccessMeasurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Author(s) -
Frank G. Rücker,
Mridul Agrawal,
Andrea Corbacioglu,
Daniela Weber,
Silke KappSchwoerer,
Verena I. Gaidzik,
Nikolaus Jahn,
Thomas Schroeder,
Mohammed Wattad,
Michael Lübbert,
Elisabeth Koller,
Thomas Kindler,
Katharina S. Götze,
Mark Ringhoffer,
Jörg Westermann,
Walter Fiedler,
Heinz A. Horst,
Richard Greil,
Roland Schroers,
Karin Mayer,
Thomas Heinicke,
Jürgen Krauter,
Richard F. Schlenk,
Felicitas Thol,
Michael Heuser,
Arnold Ganser,
Lars Bullinger,
Peter Paschka,
Hartmut Döhner,
Konstanze Döhner
Publication year - 2019
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2019001425
Subject(s) - cumulative incidence , medicine , minimal residual disease , oncology , gastroenterology , incidence (geometry) , myeloid leukemia , bone marrow , cohort , optics , physics
Key Points MRD assessment in t(8;21) AML allows identification of patients at high relapse risk at defined time points during treatment and follow-up. MRD− after treatment is the most favorable factor for relapse risk and survival, and serial MRD analyses define cutoffs predicting relapse.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom